Recent studies indicate that Skp2 deficiency renders Her2-positive breast cancer cells more sensitive to Herceptin treatment and prolongs the survival of Her2-positive patients, highlighting that Skp2 is an appealing therapeutic target to combine with Herceptin for cancer treatment13. This evidence concerns the gene SKP2 and breast carcinoma.